Compare Enovix Corporation (ENVX) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Humana Inc — how do they compare? Enovix Corporation trades at $4.85 (market cap $1.11B), while Humana Inc trades at $408.38 (market cap $48.96B). The key difference: Humana Inc is far larger — about 44.1× Enovix Corporation's market cap, and Humana Inc pays a 0.87% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals.
| ENVX | HUM | |
|---|---|---|
Market Cap | $1.11B | $48.96B |
Sector | Technology | Health |
52-Week High | $15.93 | $409.42 |
52-Week Low | $4.84 | $163.67 |
Enterprise Value | $1.13B | $58.00B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $4.855, down 4.05% today amid bearish technical signals. The company shows strong revenue growth potential with recent earnings beats but operates at a significant loss, reflected in a -499.64% net margin. Positive sentiment is driven by analyst consensus with a $12.75 price target and recent operational hires from Apple, though cash flow remains negative as production scales.
Outlook hinges on successful manufacturing ramp-up and smartphone battery qualification. High execution risk and cash burn present challenges, but leadership in silicon-anode technology offers long-term upside if commercial targets are met. Investors face volatility but potential reward from current discounted levels.
Humana (HUM) trades at $406.70, up 0.17% on the day, and is currently above its consensus price target. The stock shows a bullish technical signal with strong moving average support, though oscillators are neutral. Fundamentally, the company has beaten earnings expectations for three consecutive quarters and is executing a strategic shift from membership growth to profitability, targeting a 3% Medicare Advantage margin by 2028. Revenue has grown consistently from $92.9B in 2022 to $129.7B in 2025.
The outlook is mixed. The company's strategic pivot and recent contract wins like the Illinois Medicaid contract present growth opportunities. However, significant risks include multiple legal investigations into statements on healthcare costs, declining net profit margins (from 3.02% in 2022 to 0.91% in 2025), and a high P/E ratio of 43.52. Analyst sentiment is cautious, with a majority 'Hold' rating and a consensus price target 13% below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
